Articles tagged with Cancer Treatments
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
Researchers will develop genetic boosters and "two-factor authentication" for CAR T cell therapy, targeting HER2-positive lung, breast, and colon tumors. The project aims to improve the efficacy of CAR T cells against solid tumors while reducing collateral damage.
The collaboration aims to eliminate barriers to screening and access for medically underserved women, leveraging data science and community-based research to develop targeted solutions. By listening to residents' experiences and challenges, USC and Novartis will create lasting improvements in breast cancer care.
Researchers at Rutgers University used simulation to identify bottlenecks in their blood cancer clinic and implemented changes that reduced visit times from 90 minutes to less than 30 minutes. The approach could be applied to other medical oncology offices, improving efficiency and patient care.
Researchers have identified immune markers that can help doctors determine which breast cancer patients are unlikely to benefit from chemotherapy. The new AI-based method analyzes the body's own immune cells found near a tumor, providing additional insight to identify patients who can safely have chemotherapy withheld.
Researchers develop AI framework using principles of superposition and entanglement to tailor cancer treatment to patients' entire molecular background. The technique predicts health outcomes and suggests genes to target, outperforming standard biomarkers in clinical trials.
Researchers at Salk Institute uncover an unexpected role for HDAC enzymes in controlling critical genes involved in DNA repair, making pancreatic cells more vulnerable to therapies that induce DNA damage. This finding paves the way for new treatment strategies combining entinostat with DNA-damaging therapies.
Dr. Nowicki's research aims to develop a next-generation CAR-T cell therapy targeting GD2, a protein found on osteosarcoma cells, with enhanced immune-signaling molecule TNF-alpha. The grant will support preclinical studies to evaluate safety and effectiveness in laboratory and animal models.
A target trial emulation study found that delaying treatment of moderate pre-cancerous cervical cells (CIN 2) does not increase three-year cancer risk and reduces unnecessary excisions. The study suggests it may be safe to delay treatment, especially for lower-risk CIN 2, by adopting careful follow-up strategies.
Researchers developed DNA tetrahedrons with Vitamin E-derived molecules for targeted cancer treatment, enhancing cellular uptake and improving anticancer efficacy. The modification triggered oxidative stress in cancer cells, leading to programmed cell death.
Researchers at UC Irvine have discovered a mechanism that combines DNA damage and inflammatory signaling in tumor cells, potentially improving cancer treatment response. The study found that a combination of PARP inhibitors and TOP1 blockers triggers an 'alarm signal' inside cancer cells, alerting the immune system to eliminate them.
Scientists at VUB mapped healthy pancreas cells down to the cellular level, discovering rare cells with properties similar to aggressive tumour cells. This fundamental discovery may offer opportunities for early detection of pancreatic cancer, currently one of the most difficult diseases to treat.
Rice University has received a $2 million CPRIT award to advance cancer research, including new studies in immunotherapy and ovarian cancer. The funding will support the expansion of the Genetic Design and Engineering Center, which provides a centralized hub for DNA tools used in cancer research.
A recent clinical trial demonstrated that an all-oral drug combination of decitabine-cedazuridine and venetoclax is effective in treating acute myeloid leukemia (AML) in older patients. The regimen showed strong response rates and survival outcomes, with nearly half of patients achieving complete response.
Researchers developed multifunctional metal–organic framework nanoparticles that degrade HK-2, suppress glycolysis, and induce cuproptosis. CHNDs showed stronger anticancer activity than either the HK-2 degrader or the copper nanoplatform alone, disrupting protein homeostasis and cancer energy metabolism.
The study provides new insight into how cells recognize and remove harmful DNA bases using human SMUG1 enzyme. The enzyme removes uracil and related damaged bases from DNA to prevent permanent mutations.
Researchers have tested a new experimental cancer drug called gamitrinib in its first-in-human study. Gamitrinib is designed to target the mitochondria of cancer cells, where it can disrupt their energy systems.
Researchers developed a personalized risk prediction model to identify cancer patients who may struggle with treatment costs, medical debt, and anxiety. The model uses patient information to estimate the likelihood of financial toxicity, balancing detection sensitivity with minimizing false alarms.
Researchers analyzed tumor samples from over a thousand patients and found that TP53 gene mutations can worsen prognosis and reduce effectiveness of targeted therapies. The study suggests incorporating genetic testing into public health services to guide personalized treatment choices.
The study found that adjuvant nivolumab did not improve disease-free survival in patients with resected non–small cell lung cancer. The treatment was also not effective in sensitizing EGFR and ALK alterations.
Researchers at Mount Sinai discovered that focused irradiation can help CAR-T cells survive longer and work more effectively inside tumors. Irradiation turns dendritic cells into a local source of stimulation for CAR-T cells, promoting durable control of advanced lung tumors.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...
Two new international studies found that healthy lifestyles can have a protective effect on childhood cancer survivors, reducing the risk of chronic health problems. The studies suggest that physical activity, a healthy weight, and other lifestyle factors can significantly reduce the burden of disease in adulthood.
Research suggests that commonly used anemia medications can inhibit tumor growth and prevent new blood vessel formation, offering a potential dual approach to treating both conditions. The findings open up new possibilities for treating cancer in patients with anemia, who currently face separate treatment goals.
The National Comprehensive Cancer Network (NCCN) has launched a new free service providing weekly email updates on changes to evidence-based guidelines for cancer prevention, screening, treatment, and supportive care. The service aims to keep healthcare providers up-to-date with rapidly evolving evidence-based recommendations.
Researchers discovered that degrading mutant KRAS protein leads to greater lung cancer regression and more durable antitumor responses than conventional inhibitors. The study also identifies resistance mechanisms distinct from those previously described, offering new insights into targeted protein degradation therapies.
Researchers developed targeted platinum-antibody conjugates that effectively enhance tumor immunogenicity and promote anti-tumor immunity. The low-dose platinum delivery strategy showed strong synergy with anti-PD-1 therapy, achieving tumor suppression superior to monotherapy or simple combination treatment.
Researchers at MUSC Hollings Cancer Center have identified a potential way to reduce relapse in medulloblastoma by targeting tumor cells most likely to survive treatment and drive regrowth. The dual-pathway approach, focusing on CK1α, shows promise in preclinical models.
A study by University of Birmingham researchers has identified a new biomarker associated with response to therapy in Ewing Sarcoma and other tumour types. Patients with high aneuploidy scores were significantly more likely to benefit from the treatment, which combines irinotecan and PARP inhibitors.
The MAF Test predicts breast cancer prognosis and helps identify patients who may benefit from treatment. In South Korea, the test could improve survival rates for approximately 34,000 newly diagnosed breast cancer patients each year.
Physicians at Mount Sinai recommend a more patient-centered approach to evaluating skin toxicities in cancer treatments, prioritizing symptom burden and quality of life over treatment type. This new framework could enhance consistency across clinical trials and improve the accuracy of reporting.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.
The National Comprehensive Cancer Network has launched a new version of its Distress Thermometer and Problem List in over 70 languages to screen patients for mental, physical, social, or spiritual distress. The tool aims to enhance cancer care by identifying psychological distress and providing support.
A new cytokine-armored CAR-T cell therapy has been developed to attack aggressive brain tumors in mice while reducing side effects. The approach recruits the body's immune system using IL-12 and DR-18 proteins, strengthening the anti-cancer response and improving tumor control.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
Researchers from The University of Osaka discovered that only a small proportion of CD8 T cells undergo sustained clonal expansion in multiple myeloma immunotherapy, leading to the strongest anti-tumor response. Early immune activity could help predict which cells will become effective cancer fighters.
Researchers found that a common asthma drug can help fight aggressive cancers by blocking the CysLTR1 molecule. The study used mouse models and human tissue samples to demonstrate its potential in treating triple-negative breast cancer and other tough tumors.
An AI technology successfully plans life-saving radiotherapy for cervical and prostate cancers, bridging the workforce gap and enabling more people to be treated. The ARCHERY trial found that the AI technology can achieve international best-practice radiotherapy planning in over 95% of cervical cancer cases.
Researchers found that stereotactic body radiotherapy (SBRT) improved progression-free survival by 15.6 months, compared to 20.6 months without targeted therapy. The treatment also showed no significant impact on quality-of-life measures.
Researchers have identified a hidden mechanism explaining why breast cancer can return years after successful treatment. Slow-growing breast cancer cells can form microscopic tumours that silently tick away in distant organs, evading detection for decades.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
A recent study reveals that combining iNKT cell therapy with antigen-presenting cells activated by a lipid compound triggers effective antitumor immunity. The therapy generates memory-phenotype T cells that can recognize and respond to specific threats, offering a promising personalized approach to cancer treatment.
A NIH-funded study discovered that testosterone may play a key role in limiting brain tumor growth in men by suppressing inflammation and stress hormone production. Analysis of over 1,300 men with glioblastoma found that supplemental testosterone was significantly associated with improved survival rates.
A new CRISPR protein, Cas12a2, has shown potential for killing sick cells while leaving healthy ones untouched. Researchers have tested its effectiveness in destroying cancer cells and virus-infected cells with promising results.
Researchers at UT MD Anderson Cancer Center have made significant advancements in targeted therapy treatments for advanced lung cancer and early-stage classical Hodgkin lymphoma. The studies showcase high response rates with novel combination therapies and a new understanding of how an enzyme affects infertility and cancer progression.
A study published in Cell Reports Medicine found that inhibiting RNase H2 can cause significant damage to DNA and activate the innate immune system to produce signals that attract T cells to attack the tumor. This approach could lead to improved patient outcomes for patients with triple-negative breast cancer.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
Researchers at Rutgers University tested the efficacy of Bright IDEAS, a problem-solving skills training intervention, in reducing depression and anxiety symptoms and improving health-related quality of life among young adults with cancer. The study found significant reductions in symptoms and improvements in quality of life compared t...
Researchers from UH, Baylor College of Medicine and MD Anderson Cancer Center propose a new treatment approach for Crohn's disease by targeting the stress signal that fuels inflammation. They found that repurposing two existing cancer medications can promote natural repair and regeneration of the intestinal lining.
Binghamton University Professor L. Nathan Tumey is working on developing new chemical technologies for antibody-drug-conjugates to push the boundaries of what can be accomplished in ADCs. The goal is to awaken tumor-associated immune cells and prevent cancer regrowth.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
A new study from Tulane University found that extra sets of chromosomes in tumor cells make them more mobile and likely to engulf neighboring cells. This stress response triggers an abundance of proteins, reprogramming the cells for motility and phagocytosis.
A new treatment using low-dose nivolumab injections into precancerous oral lesions significantly reduced lesion size and risk of cancer progression. The study showed a 60% average reduction in lesion size and complete pathologic response in six patients, with no dose-limiting side effects.